AnteoTech builds traction in life sciences business
Chemicals and advanced materials company AnteoTech has two distinct business units Its life sciences unit is focused on in vitro diagnostics with the core product AnteoBindVaccine giant Serum Institute of India is among…

- Chemicals and advanced materials company AnteoTech has two distinct business units
- Its life sciences unit is focused on in vitro diagnostics with the core product AnteoBind
- Vaccine giant Serum Institute of India is among Anteotech’s customers with the company looking to expand its global customer base
AnteoTech (ASX: ADO) is classified by the Australian Securities Exchange as a materials company but part of its offering sits in life sciences, which means it could also be technically part of the healthcare sector.
CEO and managing director Merrill Gray described ADO as a chemicals and advanced materials company with a proprietary platform developed over more than 20 years.
“Our platform is a transition metal-ion complex that can be used in different applications,” Gray told Stockhead.
ADO commercialises this platform across two distinct business units.
Its origins are in life sciences with a focus on in vitro diagnostics (IVD), namely tests and instruments used on biological samples to detect disease, monitor health and guide treatments.
“What we have which is really unique is a molecular level technology where we bind molecules to molecules and molecules to surfaces,” Gray said.
“This is why our core product in life sciences is called AnteoBind because it’s that binding (co-ordination bonds) of molecules to other molecules or surfaces that is our core offering.”
Since 2018, ADO’s second business unit has been in advanced battery technologies with the focus on high-silicon anodes with its Ultranode technology and performance additives, which improve separators, primer coatings and other aspects of the functioning of batteries.
Gray, who joined the board in January 2025 and was appointed CEO and managing director on an interim basis in April 2025 before transitioning to the roles permanently in August last year, is focused on growing ADO’s two core business units.
“There are opportunities in other markets, but my job is commercialising the products that we already have in the two established business units,“ she said.
Member of national research biosensor hub
ADO is a member of MOBIUS, the Australian Research Council (ARC) Research Hub for Molecular Biosensors at Point-of-Use, which is led by La Trobe University.
Launched in August 2025, the five-year, $4.7 million project links six universities with more than 20 industry partners, with the aim of growing Australia’s biosensor sector.
Molecular biosensors are devices that detect specific molecules in samples such as bodily fluids, food or air, and turn that into a result. Familiar examples include home blood glucose meters and pregnancy tests.
The Covid-19 pandemic exposed a gap in Australia’s molecular biosensors capability, when rapid antigen tests had to be imported because there was no local manufacturing capacity.
ADO knows that gap first-hand. During the pandemic, it attempted to manufacture and bring to market a complete Australian rapid lateral flow diagnostic test.
It was an ambitious effort that ultimately missed the mark. However, Gray said the experience proved valuable because of the in-depth knowledge gained by the team.
“It taught the company that managing end-to-end packaging, assembly, and raw material supply chains at scale were not our core strength and reinforced that our true value lies in supplying our high-margin chemicals,” Gray said.
ADO now supplies AnteoBind and its next-generation formulation, AnteoBind NXT, as chemical additives to enhance IVD products across multiple platforms.
“If opportunities come up for great Australian technology that needs help along the commercialisation pathway with proof of concept, we do have a lot to offer and we are certainly there as part of our involvement with MOBIUS,” Gray said.
‘Bioconjugation is AnteoTech’s specialisation’
Breaking down the science Gray said essentially, “bioconjugation is AnteoTech’s real specialisation”.
“Biomolecules are the fundamental building blocks of living organisms and essential to biological functions,” she said.
“The process of attaching biomolecules to other molecules or surfaces is known as Bioconjugation, which is a key step in IVD.
“It allows disease markers to be captured and visualised using different assay techniques such as lateral flow, chemiluminescence and ELISA.”
Gray said billions of diagnostic tests were performed globally every year across these platforms.
“AnteoBind NXT preferentially attaches antibodies to surfaces,” she said.
Reducing costs and improving sensitivity
Gray said AnteoBind improved antibody orientation, maximised assay sensitivity and minimised test antibody and other material usage.
She said antibodies could be one of the most expensive parts of any diagnostic test comprising 35% to 70% of test costs.
AnteoBind has been found to deliver substantial improvements to IVD developers including up to 90% reduction in antibody requirements for assays.
Other benefits include up to 45 times higher signal strength compared with traditional chemistries, enabling far greater sensitivity to detect trace amounts of biomarkers, and coating stability of more than 12 months.
“Manufacturers can coat large batches of magnetic particles or plates in advance, eliminating batch-to-batch variability and reducing production waste,” Gray said.
Global commercialisation strategy
ADO is generating revenue from its life sciences business and counts Indian vaccine giant Serum Institute of India among its customers.
“We’re one of the few small caps in ASX life sciences that is revenue-generating,” Gray said.
In July 2024, ADO signed a five-year purchase deal with Serum, with minimum take-or-pay orders of US$370,000 a year, or about US$1.8m over the term.
Serum is the world’s largest vaccine maker by number of doses produced and s more than 1.5 billion a year.
Its vaccines include polio, diphtheria, tetanus, pertussis, Hib, BCG, recombinant hepatitis B, measles, mumps, rubella, pneumococcal and Covid-19.
ADO said at the time that AnteoBind had shown advantages over other methods of quality testing and control, and that it was becoming an integral part of Serum’s vaccine development and production process.
Gray said the company’s focus now was turning a growing pipeline into more customers. ADO has a constantly growing database of life sciences contacts along with a dedicated sales and marketing team.
ADO supplies developers and manufacturers across four diagnostic test platforms, including point-of-care (POC) tests such as lateral flow, chemiluminescence immunoassays (CLIA), enzyme-linked immunosorbent assay (ELISA) plates and biosensors.
“We have a record number of samples now out for evaluation with IVD manufacturers across these platforms,” Gray said.
‘The life sciences business is on the move’
In India, Japan and South Korea, ADO has appointed distributors to support business growth. It is also working with Austrade and Trade and Investment Queensland in all these countries.
In the US and Europe, the company is also working to expand its customer base and establish strategic partnerships in these key markets to rapidly increase the volume of sales.
One option is to work with particle and plate makers to co-develop AnteoBind-activated particles and plates.
Gray said this could give ADO access to its partners’ established customer bases. The company is also open to bundling and co-branded, white-label or recurring supply agreements of chemicals for inclusion in customers products.
ADO has identified multiple potential partners and since earlier in 2026 has been working with an unnamed large life sciences company in CLIA.
The other route to market is to collaborate with diagnostic test developers to build AnteoBind into new platforms right from the start. The company has also identified several early-stage developers and is working with them across various platforms.
“The life sciences business is on the move,” Gray said.
“I’d like to say that we’re on the cusp, but every customer does have its own specific needs, and they do have to undertake their own specific evaluation processes, which can take time.
“But we’ve put a massive effort in getting to where we are now, and we will just keep expanding our potential customer base with well qualified leads who get that we have something unique to offer.”
This article was developed in collaboration with AnteoTech, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
The post AnteoTech builds traction in life sciences business appeared first on Stockhead.
Figures reflect the source report and its stated period. This article is for information and is not investment advice.



